Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Gal-ARV 771, Gal-ARV771 |
Target |
Action inhibitors |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), BET inhibitors(Bromodomain and extra terminal domain protein inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 09 May 2024 |